PMA increased PKC1β level and reduced RIPK4 level in WM266.4 melanoma cells after 12–48 h of treatment (Figure 4b), and concomitantly inhibited the WM266.4 cell motility (Figure 4c). The gene discussed is RIPK4; the disease is melanoma.